Relay Therapeutics (RLAY) Enterprise Value (2020 - 2026)

Relay Therapeutics (RLAY) has reported Enterprise Value for 8 consecutive years, with -$642.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 586.39% year-over-year to -$642.1 million; the TTM figure through Mar 2026 stood at -$642.1 million (down 586.39% YoY), while the FY2025 annual figure was -$554.5 million, down 346.16% from the prior year.
• Enterprise Value eased to -$642.1 million in Q1 2026 per RLAY's latest filing, from -$554.5 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$91.6 million in Q3 2025 and bottomed at -$642.1 million in Q1 2026.
• Historically, Enterprise Value has averaged -$199.7 million across 5 years, with a median of -$145.9 million in 2023.
• Annual changes were most pronounced in 2022 — Enterprise Value jumped 58.57% — and 2026, when it tumbled 586.39%.
• Relay Therapeutics' Enterprise Value stood at -$151.8 million in 2022, then climbed by 5.31% to -$143.7 million in 2023, then advanced by 13.53% to -$124.3 million in 2024, then slumped by 346.16% to -$554.5 million in 2025, then declined by 15.79% to -$642.1 million in 2026.
• Business Quant data shows RLAY's Enterprise Value at -$642.1 million in Q1 2026, -$554.5 million in Q4 2025, and -$91.6 million in Q3 2025.